Unknown

Dataset Information

RhoA enhances osteosarcoma resistance to MPPa-PDT via the Hippo/YAP signaling pathway.


ABSTRACT:

Background

Osteosarcoma (OS) is the most prevalent primary bone malignancy affecting adolescents, yet the emergence of chemoradiotherapeutic resistance has limited efforts to cure affected patients to date. Pyropheophorbide-α methyl ester-mediated photodynamic therapy (MPPa-PDT) is a recently developed, minimally invasive treatment for OS that is similarly constrained by such therapeutic resistance. This study sought to explore the mechanistic basis for RhoA-activated YAP1 (YAP)-mediated resistance in OS.

Methods

The relationship between YAP expression levels and patient prognosis was analyzed, and YAP levels in OS cell lines were quantified. Immunofluorescent staining was used to assess YAP nuclear translocation. OS cell lines (HOS and MG63) in which RhoA and YAP were knock

SUBMITTER: Zhan F 

PROVIDER: S-EPMC8501741 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature